Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
14.72
+0.27 (1.87%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Arcutis Biotherapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Arcutis Biotherapeutics stock have an average target of 18.8, with a low estimate of 15 and a high estimate of 21. The average target predicts an increase of 27.72% from the current stock price of 14.72.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Arcutis Biotherapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 3 | 4 | 4 | 4 |
| Buy | 1 | 0 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +35.87% | Apr 9, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Apr 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +29.08% | Apr 3, 2025 |
| Needham | Needham | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +35.87% | Apr 3, 2025 |
| Jefferies | Jefferies | Strong Buy Maintains $16 → $19 | Strong Buy | Maintains | $16 → $19 | +29.08% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
310.51M
from 196.54M
Increased by 57.99%
Revenue Next Year
438.57M
from 310.51M
Increased by 41.24%
EPS This Year
-0.66
from -1.16
EPS Next Year
0.25
from -0.66
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 344.3M | 567.0M | 771.8M | ||
| Avg | 310.5M | 438.6M | 602.5M | ||
| Low | 278.8M | 333.1M | 362.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 75.2% | 82.6% | 76.0% | ||
| Avg | 58.0% | 41.2% | 37.4% | ||
| Low | 41.8% | 7.3% | -17.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.50 | 1.42 | 2.82 | ||
| Avg | -0.66 | 0.25 | 1.34 | ||
| Low | -0.79 | -0.25 | 0.13 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,015.9% | ||
| Avg | - | - | 428.0% | ||
| Low | - | - | -49.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.